Therapeutic use of anti-cs1 antibodies

Abstract

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

What is claimed is: 
     
         1 . An antibody or an antigen-binding fragment thereof, wherein said antibody binds to CS1 and inhibits immunoglobulin secretion. 
     
     
         2 . The antibody or the antigen-binding fragment according to  claim 1 , wherein said antibody inhibits the proliferation of leukocytes. 
     
     
         3 . The antibody or the antigen-binding fragment according to  claim 1 , wherein said antibody inhibits the proliferation of cancer cells. 
     
     
         4 . The antibody or the antigen-binding fragment according to  claim 1 , wherein said antibody triggers cytotoxic effects on cells expressing CS1 or enhances cytotoxicity mediated by immune cells. 
     
     
         5 . The antibody or antigen binding fragment of  claim 4 , wherein said antibody triggers ADCC-mediated cytotoxicity of cells expressing CS1. 
     
     
         6 . The antibody or the antigen-binding fragment according to  claim 1 , wherein said antibody binds to substantially the same eptitope as the antibody produced by a hybridoma cell line having ATCC accession number PTA-5091 or a Luc63 antibody. 
     
     
         7 . The antibody or antigen-binding fragment according to  claim 1 , wherein said antibody is produced by a hybridoma cell line having ATCC accession number PTA-5091. 
     
     
         8 . The antibody or the antigen-binding fragment according to  claim 1 , wherein said antibody is produced by a hybridoma cell line expressing Luc63 antibody. 
     
     
         9 . The antibody according to  claim 1 , wherein said antibody is a monoclonal antibody. 
     
     
         10 . The antibody according to  claim 9 , wherein said monoclonal antibody is a chimeric antibody, a humanized antibody, or a fully human antibody. 
     
     
         11 . The antibody according to  claim 1 , wherein said antibody is conjugated with a cytotoxic agent. 
     
     
         12 . A pharmaceutical composition comprising a pharmaceutical carrier and the antibody according to  claim 1 . 
     
     
         13 . A method of inhibiting proliferation of CS-1 expressing cells comprising contacting said cells with an effective amount of an antagonist of CS1. 
     
     
         14 . The method according to  claim 13 , wherein said CS-1 expressing cells are plasma cell cancer cells. 
     
     
         15 . The method according to  claim 13 , wherein said protein is an antibody or an antigen-binding fragment that binds to CS1. 
     
     
         16 . The method according to  claim 15 , wherein said antibody is monoclonal. 
     
     
         17 . A method for treating an individual with plasma cell cancer comprising administering an antagonist that specifically binds to a polypeptide encoded by SEQ ID NO:2.